<DOC>
	<DOCNO>NCT00061178</DOCNO>
	<brief_summary>The purpose study determine whether rhuMAb VEGF ( Bevacizumab ) safe effective treatment renal cell cancer treatment fail .</brief_summary>
	<brief_title>Efficacy Safety Study rhuMAb VEGF Treat Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Written inform consent Histologically confirm , metastatic renal cell cancer ( RCC ) clear cell histology Clinical radiographic evidence disease progression ( assessed investigator review Sponsor ) completion one , one , cytokinebased regimen metastatic disease At least 21 day since prior therapy RCC Prior nephrectomy Use acceptable mean contraception ( potentially fertile men woman ) ECOG performance status 0 1 Life expectancy &gt; = 3 month Age 18 year old RCC papillary collectingduct type More one nonsurgical therapy metastatic RCC ( note medroxyprogesterone acetate use physiologic replacement birth control consider therapy RCC purpose study ) Prior treatment thalidomide Radiotherapy within 14 day Day 0 Current , recent ( within 21 day Day 0 ) , plan participation experimental drug study Pregnant breastfeeding subject Any follow screen clinical laboratory value : 24hour urine collection &gt; = 1 g protein ; Serum creatinine &gt; 2.0 mg/dL ; Absolute neutrophil count ( ANC ) &lt; 500/mL ; Platelet count &lt; 75,000/mL ; INR &gt; = 1.5 ; Total bilirubin &gt; 2.0 mg/dL ; AST ALT &gt; 5 x upper limit normal ( ULN ) subject document liver metastases &gt; 2.5 x ULN subject without evidence liver metastasis ; Hemoglobin &lt; 9 gm/dL ( may transfuse receive epoetin alfa [ e.g. , Epogen ] maintain exceed level ) Other invasive malignancy within 5 year randomization ( squamous basal cell carcinoma skin ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Inability comply study and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>